دورية أكاديمية
أعرض في EDS

[Recent advances in the development of vaccines against hemorrhagic fevers caused by arenaviruses].

التفاصيل البيبلوغرافية
العنوان: [Recent advances in the development of vaccines against hemorrhagic fevers caused by arenaviruses].
عنوان ترانسليتريتد: Les fièvres hémorragiques causées par les arénavirus : de récentes avancées vaccinales.
المؤلفون: Mateo M; Institut Pasteur, Université Paris Cité, Unité de biologie des infections virales émergentes, Paris, France - Centre international de recherche en infectiologie (CIRI), université de Lyon, Inserm U1111, école normale supérieure de Lyon, université Lyon 1, CNRS UMR5308, 69-007, Lyon, France., Baize S; Institut Pasteur, Université Paris Cité, Unité de biologie des infections virales émergentes, Paris, France - Centre international de recherche en infectiologie (CIRI), université de Lyon, Inserm U1111, école normale supérieure de Lyon, université Lyon 1, CNRS UMR5308, 69-007, Lyon, France.
المصدر: Medecine sciences : M/S [Med Sci (Paris)] 2023 Nov; Vol. 39 (11), pp. 855-861. Date of Electronic Publication: 2023 Nov 29.
نوع المنشور: English Abstract; Journal Article
اللغة: French
بيانات الدورية: Publisher: EDK Country of Publication: France NLM ID: 8710980 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1958-5381 (Electronic) Linking ISSN: 07670974 NLM ISO Abbreviation: Med Sci (Paris) Subsets: MEDLINE
أسماء مطبوعة: Publication: <2003->: Paris : EDK
Original Publication: [Paris] : Flammarion, [1985-
مواضيع طبية MeSH: Arenavirus* , Hemorrhagic Fevers, Viral*/prevention & control , Lassa Fever*/prevention & control , Arenaviridae Infections*/prevention & control , Viral Vaccines*/therapeutic use, Humans
مستخلص: Arenaviruses are a global threat, causing thousands of deaths each year in several countries around the world. Despite strong efforts in the development of vaccine candidates, vaccines against Lassa fever or Bolivian and Venezuelan hemorrhagic fevers are yet to be licensed for a use in humans. In this synthesis, we present the arenaviruses causing fatal diseases in humans and the main vaccine candidates that have been developed over the past decades with an emphasis on the measles-Lassa vaccine, the first Lassa vaccine ever tested in humans, and on the MOPEVAC platform that can potentially be used as a pan-arenavirus vaccine platform.
(© 2023 médecine/sciences – Inserm.)
References: Sironi M, Forni D, de la Torre J.-C. Mammarenavirus Genetic Diversity and Its Biological Implications. Cur Top Microbiol Immunol 2023; 439 : 265–303.
Buchmeier MJ, de la Torre JC, and Peters CJ. Arenaviridae. Fields virology. Philadelphia, Pennsylvania, USA. : Lippincott Williams & Wilkins, Wolters Kluwer 2013 : pp. 1283–303.
Briese T, Paweska JT, McMullan LK, et al. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 2009 ; 5 : e1000455.
Monath TP, Newhouse VF, Kemp GE, et al. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 1974 ; 185 : 263–265.
Olayemi A, Cadar D, Magassouba N, et al. New Hosts of The Lassa Virus. Sci Rep 2016 ; 6 : 25280.
McCormick JB, Fisher-Hoch SPLassa fever. Cur Top. Microbiol Immunol 2002 ; 262 : 75–109.
Merson L, Bourner J, Jalloh S, et al. Clinical characterization of Lassa fever : A systematic review of clinical reports and research to inform clinical trial design. PLoS Negl Trop Dis 2021; 15 : e0009788.
Robinson JE, Hastie KM, Cross RW, et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 2016 ; 7 : 11544.
Ugwu C, Olumade T, Nwakpakpa E, et al. Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria. Sci Rep 2022; 12 : 22330.
Garry RF. Lassa fever - the road ahead. Nat Rev Microbiol 2023; 21 : 87–96.
Eberhardt KA, Mischlinger J, Jordan S, et al. Ribavirin for the treatment of Lassa fever : A systematic review and meta-analysis. Int J Infect Dis 2019 ; 87 : 15–20.
Salam apr., Cheng V, Edwards T, et al. Time to reconsider the role of ribavirin in Lassa fever. PLoS Negl Trop Dis 2021; 15 : e0009522.
Ambrosio A, Saavedra M, Mariani M, et al. Argentine hemorrhagic fever vaccines. Hum Vaccin 2011 ; 7 : 694–700.
Silva-Ramos CR, Faccini-Martinez AA, Calixto OJ, Hidalgo M. Bolivian hemorrhagic fever : A narrative review. Travel Med Infect Dis 2021; 40 : 102001.
Patterson M, Grant A, Paessler S Epidemiology and pathogenesis of Bolivian hemorrhagic fever. Curr Opin Virol 2014 ; 5 : 82–90.
Silva-Ramos CR, Montoya-Ruiz C, Faccini-Martinez AA, Rodas J.-D. An updated review and current challenges of Guanarito virus infection, Venezuelan hemorrhagic fever. Arch Virol 2022; 167 : 1727–38.
Nastri AC, Duarte-Neto AN, Casadio LVB, et al. Understanding Sabia virus infections (Brazilian mammarenavirus). Travel Med Infect Dis 2022; 48 : 102351.
Loayza Mafayle R, Morales-Betoulle ME, Romero C, et al. Chapare Hemorrhagic Fever and Virus Detection in Rodents in Bolivia in 2019. N Engl J Med 2022; 386 : 2283–94.
Frank MG, Beitscher A, Webb CM, et al. South American Hemorrhagic Fevers : A summary for clinicians. Int J Infect Dis 2021; 105 : 505–15.
Levis SC, Saavedra MC, Ceccoli C, et al. Endogenous interferon in Argentine hemorrhagic fever. J Infect Dis 1984 ; 149 : 428–433.
Levis SC, Saavedra MC, Ceccoli C, et al. Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. J Interferon Res 1985 ; 5 : 383–389.
Maiztegui JI, Fernandez NJ, de Damilano AJEfficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979 ; 2 : 1216–1217.
Salami K, Gouglas D, Schmaljohn C, et al. A review of Lassa fever vaccine candidates. Curr Opin Virology 2019 ; 37 : 105–111.
Tang-Huau TL, Feldmann H, Rosenke KAnimal models for Lassa virus infection. Curr Opin Virol 2019 ; 37 : 112–117.
WHO Target Product Profile for Lassa virus Vaccine. https://www.who.int/publications/m/item/who-target-product-profile-for-lassa-virus-vaccine.
Yadouleton A, Picard C, Rieger T, et al. Lassa fever in Benin : description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus. Emerg Microbes Infect 2020; 9 : 1761–70.
Kafetzopoulou LE, Pullan ST, Lemey P, et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science 2019 ; 363 : 74–77.
Cashman KA, Wilkinson ER, Shaia CI, et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum Vacc Immunother 2017 ; 13 : 2902–2911.
Jiang J, Banglore P, Cashman KA, et al. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques. Hum Vacc Immunother 2019 : 1–9.
Ollmann Saphire E. A Vaccine against Ebola Virus. Cell 2020; 181 : 6.
Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005 ; 2 : e183.
Cross RW, Woolsey C, Prasad AN, et al. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. Cell Rep 2022; 40 : 111094.
Safronetz D, Mire C, Rosenke K, et al. A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses. PLoS Negl Trop Dis 2015 ; 9 : e0003736.
Lukashevich IS, Patterson J, Carrion R, et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 2005 ; 79 : 13934–13942.
Kiley MP, Lange JV, Johnson KMProtection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 1979 ; 2 : 738.
Lukashevich IS, Carrion R, Jr, Salvato MS, et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 2008 ; 26 : 5246–5254.
Carnec X, Mateo M, Page A, et al. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. J Virol 2018 ; 92 :.
Carnec X, Baize S, Reynard S, et al. Lassa virus nucleoprotein mutants generated by reverse genetics induce robust type I IFN response in human dendritic cells and macrophages. J Virol 2011 ; 85 : 12093–12097.
Mateo M, Reynard S, Carnec X, et al. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci Transl Med 2019; 11 : eaaw3163.
Baize S. Une vaccination efficace en dose unique contre la fièvre de Lassa. Med Sci (Paris) 2020; 36 : 844–7.
Mateo M, Reynard S, Journeaux A, et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci Transl Med 2021; 13 : eabf6348.
Mateo M, Reynard S, Pietrosemoli N, et al. Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys. Nat Commun 2023; 14 : 1352.
Tschismarov R, Van Damme P, Germain C, et al. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine : a randomised, placebo-controlled, first-in-human trial. Lancet 2023; 401 : 1267–76.
Samoilovich SR Pecci Saavedra J, Frigerio MJ, Weissenbacher MC. Nasal and intrathalamic inoculations of primates with Tacaribe virus : protection against Argentine hemorrhagic fever and absence of neurovirulence. Acta Virol 1984 ; 28 : 277–281.
McKee KT J.-R., Oro JG, Kuehne AI, et al. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 1992 ; 34 : 154–163.
Maiztegui JI, McKee KT J.-R., Barrera Oro JG, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 1998 ; 177 : 277–283.
Reynard S, Carnec X, Picard C, et al. A MOPEVAC multivalent vaccine induces sterile protection against New World arenaviruses in non-human primates. Nat Microbiol 2023; 8 : 64–76.
فهرسة مساهمة: Local Abstract: [Publisher, French] Les fièvres hémorragiques causées par les arénavirus : de récentes avancées vaccinales. [Publisher, French] Le développement de vaccins contre les arénavirus est un enjeu global. En effet, plusieurs milliers de personnes meurent chaque année de la fièvre de Lassa en Afrique occidentale et les virus Machupo, Guanarito ou Chapare continuent de ré-émerger en Amérique du Sud. Pourtant, il n’existe à ce jour aucun vaccin validé pour une utilisation dans l’espèce humaine pour lutter contre ces arénavirus. Dans cette synthèse, nous présentons les différents arénavirus causant des maladies mortelles chez l’espèce humaine et les principaux candidats vaccins développés au cours des dernières décennies contre ces virus. Nous décrivons plus particulièrement le vaccin rougeole-Lassa, premier vaccin contre la fièvre de Lassa à avoir été testé dans l’espèce humaine, et la plateforme MOPEVAC qui permet de générer avec succès des vaccins mono- ou multivalents contre potentiellement tous les arénavirus pathogènes connus.
المشرفين على المادة: 0 (Viral Vaccines)
تواريخ الأحداث: Date Created: 20231129 Date Completed: 20231130 Latest Revision: 20231130
رمز التحديث: 20240829
DOI: 10.1051/medsci/2023162
PMID: 38018929
قاعدة البيانات: MEDLINE
الوصف
تدمد:1958-5381
DOI:10.1051/medsci/2023162